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Abstract Antiretroviral therapy has revolutionised the treat-
ment for people living with HIV (PLWH). Where antiretrovi-
ral coverage is high, the treatment paradigm for HIV-disease is
now one of managing the long-term consequences of the virus
and its treatment rather than the consequences of untreated
HIV-disease such as immunosuppression and opportunistic
infections. One such long-term consequence is HIV-
associated cognitive impairment which is reported to occur
in up to 50 % of treated PLWH and has been associated with
poorer outcomes. Given the ageing cohort and increased fre-
quency of comorbidities, the prevalence of symptomatic cog-
nitive impairment may increase with time. High quality evi-
dence for management strategies including screening, diagno-
sis and treatment of HIV-associated cognitive impairment are
lacking and in general guidelines are based on best clinical
practice. In this article, we assessed recent guidelines
concerning the management of HIV-associated cognitive im-
pairment by performing a systematic review of theMEDLINE
database using PubMed. We report that, in general, guidelines
from around the world regarding the management of HIV-
associated cognitive impairment are converging. Screening
is generally not recommended in asymptomatic PLWH.
Diagnosis of HIV-associated cognitive impairment should be
made only after a comprehensive assessment and exclusion of
other potential causes. Antiretroviral therapy forms the corner-
stone of management of HIV-associated cognitive impairment
and should be guided by plasma and cerebrospinal fluid (CSF)
genotype(s).
Keywords HIV-associated cognitive disorder . Cognitive
impairment . HIV . Guidelines
Introduction
With the widespread availability of highly tolerable and effi-
cacious antiretroviral therapy (ART) HIV-infection is now a
chronic manageable disease. Life expectancy approaches nor-
mal for people living with HIV (PLWH) if successfully treated
and retained in care [1]. As such, the cohort of PLWH is
ageing and the treatment paradigm has shifted from the man-
agement of immunosuppression and opportunistic infections
to the long-term consequences of HIV-infection and its treat-
ment. HIV-associated cognitive impairment (CI) has been
recognised since the early days of the epidemic with approx-
imately 15 % of those with AIDS reported to have co-existing
HIV-associated dementia (HAD). Since the introduction of
ART, the prevalence of HAD has decreased markedly but
there remains a large burden of milder forms of CI affecting
up to 50 % of PLWH [2, 3]. It is unclear at the moment
whether HIV-infection leads to accelerated or premature age-
ing [4], but, given that HIV-positive cohorts are ageing, the
number of PLWH with symptomatic CI is likely to rise.
Research to date has concentrated on the diagnosis and
management of HIV-associated CI. However, given the
shifting demographics of HIV-positive cohorts, the incidence
of other forms of neurodegenerative disease in HIV-positive
individuals, also presenting as CI, is likely to increase. This
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presents a diagnostic conundrum when faced with an HIV-
positive patient who has CI. In the pre-ART era, most HIV-
positive individuals were young and free of cardiovascular
and other end-organ comorbidities. As such, an HIV-positive
individual presenting with CI had a high pre-test probability
that this condition was HIV-related and the management was
clear—namely initiation of ART. In 2016, this is no longer the
case. PLWH have an increased burden of comorbidities even
when compared to a matched HIV-negative control popula-
tion. Reported comorbidities includes cardiovascular disease,
renal disease, hepatic disease and bone disease which may
contribute to or be associated with CI [5]. Given this and the
increasing age of the cohort, there are many possible causes of
CI in an HIV-positive individual presenting with CI, with
HIV-infection being only one (see Fig. 1 for an illustration
of the changing aetiology of CI in HIV-positive individuals).
In fact, as the majority of PLWH on ART have durable sup-
pression of HIV-replication in both the plasma and central
nervous system (CNS) compartments [6•, 7], the likelihood
that CI is directly caused by HIV-replication and associated
neuroinflammation is now decreasing. Further complicating
the matter is that in many cases the cause of CI is likely to be
multifactorial. CNS injury prior to the initiation of ART is
likely to lower the threshold for symptomatic CI, by decreas-
ing ‘physiological reserve’, following further insults such as
drug and alcohol misuse, vascular disease [8] and possibly
antiretroviral neurotoxicity from chronic treatment [9].
Guidelines are informed by research, and where high
quality research is not available guidelines may be based
on best clinical practice or opinion of the writing commit-
tee. At the current time, the majority of HIV treatment
guidelines focus on HIV-related conditions. For example,
CI guidelines will generally focus on HIV-associated CI
with management of other causes of CI in HIV-positive
individuals being less clearly defined.
In this article, we performed a systematic review of recent
guidelines concerning the management of CI in HIV. In par-
ticular, we reviewed the current guidance surrounding screen-
ing, diagnosis and treatment of HIV-associated CI.
Methodology
We performed a systematic review of the MEDLINE database
using PubMed. We searched for HIV treatment guidelines
using the search terms ‘HIV’, ‘guideline’ and ‘treatment’.
This yielded 227 articles published from 2010 onwards (last
search 19 Jan 2016). Furthermore, we also searched PubMed
using the terms ‘HIV’, ‘guideline’ and as a third term ‘CNS’,
‘cognitive’ or ‘neuro’ yielding 11, 20 and 1 article(s), respec-
tively. Only articles published in English were reviewed.
These were then appraised and if appropriate were selected
for further in depth assessment. Additionally, websites of
national and international organisations and societies that pub-
lish HIV-related guidelines, such as the World Health
Organisation (WHO), were searched in case they were not
indexed on PubMed. Given the nature of this review, i.e. of
guidelines rather than data, qualitative rather than quantitative
descriptions of our findings are presented.
National and international guidelines reviewed were pub-
lished by the Australasian Society for HIVMedicine (ASHM)
[10], British HIV Association (BHIVA) [11, 12], European
AIDS Clinical Society (EACS) [13, 14], French HIV Expert
Group [15], the International Advisory Panel on HIV Care
(IAPAC) [16], International Antiviral Society [17],
Infectious Diseases Society of America (IDSA) [18], Italian
HIV Guidelines Group [19, 20], Korean Society for AIDS
[21], Quebec HIV Care Committee [22], Thai National HIV
Guidelines Working Group [23], United States Department of
Health and Human Services (DHHS) [24, 25] and the WHO
[26–28]. In addition, important guidelines concerning HIV-
associated CI not published by national or international bod-
ies, such as the MIND Exchange Working Group, were also
used for reference purposes [29••, 30••, 31].
Results
Screening for CI
Screening for CI in both HIV-positive and HIV-negative pop-
ulations is a controversial topic. In HIV-negative populations,
screening is generally not recommended in those without
symptoms [32, 33]. This is largely due to the lack of effica-
cious treatment and concerns about over-diagnosis and in-
creased anxiety in those identified as havingmild CI at screen-
ing where prognosis is uncertain. Valcour et al provide an
excellent review of the issues surrounding screening for CI
Fig. 1 The hypothetical changing aetiology of cognitive impairment in
those with HIV (and how it may be possible to assess their contribution in
clinical studies)
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in PLWH [29••]. Although they do not make a firm recom-
mendation either for or against screening, they make the point
that, if performed, screening should use a strategy of testing
multiple cognitive domains because of likely sub-cortical na-
ture of HIV-associated CI. This effectively precludes the use
of the mini-mental state examination (MMSE) which was
originally designed to differentiate between patients with
functional and organic dementias and primarily tests ‘cortical’
domains [34].
Most HIV treatment guidelines do not make any specific
recommendations about screening for CI. Of the ones that do,
there is considerable variation in guidance reflecting the un-
certainties in the literature. The EACS v8.0 guidelines pub-
lished in 2015 recommend screening only symptomatic HIV-
positive individuals ‘without highly confounding conditions’
at diagnosis and before ART initiation and then as indicated
based on symptoms [14]. This is a subtle change from guid-
ance published a year earlier that recommended screening all
PLWH every 2 years regardless of symptoms [13]. The EACS
screening method involves asking three questions: ‘Do you
experience frequent memory loss?’; ‘Do you feel that you are
slower when reasoning, planning activities, or solving prob-
lems?’ and ‘Do you have difficulties paying attention?’.
Responses of ‘yes, definitely’ to at least one constitutes a
positive screening test necessitating further investigation.
This is different from guidance from the consensus report of
the Mind Exchange Program (2013) who recommend screen-
ing within 6 months of diagnosis, before ART initiation, every
6–12 months if high risk, every 12–24 if low risk and imme-
diately if there is any clinical deterioration (grade of evidence
5 [Oxford Centre for Evidence-Based Medicine, CEBM [35])
and grade of recommendation D) [30••]. In contrast to the
EACS guidelines that specify asking the ‘three questions’,
the Mind Exchange Working Group recommend using a
screening tool appropriate to the goal in mind (i.e. identifica-
tion of HAD or milder forms of CI), clinical environment,
clinician expertise and availability. The tests they prefer are
similar to those recommended by Valcour et al. [29••] with the
international HIV dementia scale (iHDS) noted in both for its
speed and ease of use. The Italian ART guidelines (2011)
recommend screening all PLWH with the EACS ‘three ques-
tions’ (see above). Additional screening methods they men-
tion were the iHDS or theMMSE although it was not clear the
situation where one would be preferred over the others. The
BHIVA routine monitoring guidelines (2011) are more cir-
cumspect about screening and mention a ‘general assessment
of mood and cognitive function’ should be performed pre-
ART initiation and at least annually with history and clinical
examination as appropriate [12]. In those with symptoms sug-
gestive of cognitive decline, investigations are recommended
for HIV-related CI as well as excluding possible alternative
causes. This is similar to guidance published by the IDSA in
their primary care HIV guidelines [18]. TheWHO recommend
that routine screening for mental health disorders should be
provided for key populations of PLWH in order to optimise
health outcomes and improve ART adherence [27]. However,
the preferred screening method and frequency are not
specified.
Diagnosis of CI
In general, there is agreement between guideline bodies re-
garding the diagnosis of HIV-associated CI. A comprehensive
assessment including a thorough history and examination,
screening for depression, neuropsychological testing, cerebral
MRI scanning and lumbar puncture is recommended by all
guidelines that have specific sections regarding HIV-
associated CI [10, 14, 19, 30••]. This is helpfully presented
in the form of an algorithm by the Italian HIV Guidelines
Group and EACS [14, 19]. To further guide management
plasma and cerebrospinal fluid (CSF) HIV RNA and genotyp-
ing is recommended, if available and appropriate. This is pri-
marily to identify the small proportion of patients with symp-
tomatic CI who have discordant suppression of HIV-
replication in plasma and CSF compartments—so called
‘CSF escape’ [7]. Different thresholds of discordance have
been proposed with EACS defining escape as detection of
HIV RNA in CSF, despite undetectable HIV RNA in plasma,
or a CSF HIV RNA 1 log10 copies/mL higher than concom-
itant plasma level (if detectable) [14]. The additional purpose
of CSF examination is to identify other causes of CI in appro-
priate situations (e.g. neurosyphilis). With an ageing popula-
tion, examination of CSF biomarkers to distinguish between
Alzheimer’s, HIV-associated and other dementias may be-
come more important. However, at present, quantification of
specific CSF biomarkers other than HIV RNA is not recom-
mended. The ASHM guidelines (2009) also recommend cere-
bral MR spectroscopy, if available, to aid diagnosis but this is
not specifically recommended in other guidelines.
Although there is no clear consensus on the exact tests that
should be used as part of the neuropsychological assessment,
all guidelines recommend a comprehensive battery, testing
several cognitive domains and reference the international ex-
pert consensus guidelines commonly known as the ‘Frascati
criteria’ which in the supplementary information recommend
several preferred tests for each cognitive domain [31]. The
Mind Exchange Working Group make the useful point that
the tests selected should be validated in the language and
culture of the population tested with appropriate normative
data available to interpret the results [30••].
Management of HIV-associated CI
Antiretroviral management of PLWH is a rapidly progressing
field. The recent results of the INSIGHT-START trial [36••]
have provided clarity about when to start ARTat higher CD4+
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cell counts. This has simplified ART treatment somewhat,
with all recent treatment guidelines advocating ART at any
CD4+ cell count. However, in recent years, all guidelines
previously recommended initiation of ART in those diag-
nosed with HIV-associated CI regardless of CD4+ lympho-
cyte count so it is questionable whether this new data has
impacted management in those presenting with CI who are
not receiving ART (BHIVA level of evidence 1C; Grading
of Recommendations Assessment, Development and
Evaluation [GRADE] [37]). Earlier treatment may lead to
a reduced incidence of HIV-associated CI [38], but prelim-
inary results from the INSIGHT-START neurological sub-
study suggest there to be no specific cognitive benefit in
those initiating ART immediately with a CD4+ lymphocyte
count above 500 cells/μL versus waiting to initiate ART
before the CD4+ lymphocyte count falls to around
350 cells/μL [39].
Only the previous ASHM guidelines recommend the use of
specific antiretrovirals in patients diagnosed with HIV-
associated CI with suspected favourable CNS pharmacokinet-
ics, such as zidovudine (AZT) [10]. The BHIVA guidelines
recommend standard ART aside from efavirenz (GRADE ev-
idence 1C) and nucleoside sparing regimens, such as protease
inhibitor (PI) monotherapy, which should be avoided [11].
They also make the specific point that the clinical penetration
effectiveness (CPE) score, which provides a simplified scor-
ing system based on each antiretroviral’s likely CNS exposure
[40], should not influence therapeutic decisions in patients
with HIV-associated CI commencing ART. The DHHS guide-
lines also recommend the avoidance of efavirenz in those with
HAD, favouring darunavir- or dolutegravir-based regimens
[25]. TheMIND ExchangeWorking Group is similarly guard-
ed regarding the use of CPE score to guide choice of ART,
acknowledging the uncertainty in the literature [30••].
In those receiving ART, themanagement of HIV-associated
CI is more complicated. Again, an algorithmic approach is
generally advocated depending on various factors such as
CSF HIV RNA and availability of CSF HIV genotyping and
low-copy CSF HIV RNA assays [30••]. It is generally recom-
mended that ART should be optimised based on plasma and
CSF genotypes with consideration given to likely antiretrovi-
ral CNS exposure [10, 11, 14, 19, 24, 30••]. The general ap-
proach to a HIV-positive patient with confirmed CI with no
confounding condition is summarised in Fig. 2. Although
CSF genotyping is not available in all healthcare settings, this
recommendation to assess for the presence of HIV drug resis-
tance mutations in CSF samples in guidelines allows
healthcare providers to advocate funding for this laboratory
test from healthcare funding agencies.
Monitoring/Follow-up
In common with many disease areas, data about the practical-
ities of clinical management, such as how frequently to review
patients and in what setting, are lacking. This is due to numer-
ous factors such as the heterogeneity of provision of clinical
care across the globe, physician availability and patient expec-
tation. HIV-associated CI is no different, and guidance is
based largely on longitudinal studies and expert opinion.
There is agreement between the various bodies in that a suffi-
cient duration (i.e. weeks) should elapse after an intervention
before testing is repeated due to the likely kinetics of CNS
HIV-replication and potential recovery. The ASHM recom-
mend repeat lumbar puncture, neuropsychological testing
and MRI after 12 weeks of a new antiretroviral regimen
[10]. For those with HAD, neuropsychological testing is rec-
ommended every 6 months with a repeat lumbar puncture
reserved for those with evidence of relapse. EACS recom-
mend repeating CSF examination and other tests after at least
4 weeks [14]. The Italian HIV Guidelines Group recommend
re-evaluation after 3–12 months using neuropsychological
testing depending on the severity of CI with tests repeated
annually in those with the mildest disease or who have recov-
ered [19]. The MIND Exchange Working Group recommend
more frequent monitoring [30••]. For those with HIV-
associated CI not receiving ART, reassessment is recommend-
ed monthly if possible. Those diagnosed with HAD or ‘mild
neurocognitive disorder’ (MND) commencing ARTshould be
monitored clinically, initially every 3 months and then every
6 months until a plateau in response is seen and then annually.
Fig. 2 Proposed algorithm for
the management of confirmed
cognitive impairment (assuming
no confounding condition) in
HIV-positive individuals already
receiving antiretroviral therapy
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In those with asymptomatic impairment, monitoring is recom-
mended initially after 6 months and then annually thereafter.
Conclusions
Guidelines from around the world on the management of HIV-
associated CI are converging. In general, screening for CI is
not recommended in HIV-positive populations without symp-
tomatology and diagnosis of HIV-associated CI should be
made only after a comprehensive assessment and exclusion
of other potential causes. ART and adherence forms the cor-
nerstone of management of HIV-associated CI, and any mod-
ifications to ART in subjects with HIV-associated CI should
be guided by both plasma and CSF genotype(s) in the case
where HIV-viraemia is detected.
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